
175.34 Delayed Data As of Sep 20 | ![]() Today’s Change | 174.41 Today|||52-Week Range 242.97 | -26.22% Year-to-Date |
Alnylam's (ALNY) Onpattro sNDA Gets FDA Advisory Committee Nod Sep 14 / Zacks.com - Paid Partner Content | Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study Sep 08 / Zacks.com - Paid Partner Content |
Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More Sep 08 / Zacks.com - Paid Partner Content |
Previous close | 175.66 |
Today’s open | 176.00 |
Day’s range | 174.41 - 179.49 |
Volume | 565,315 |
Average volume (3 months) | 565,981 |
Market cap | $23.1B |
Earnings growth (last year) | -29.11% |
Earnings growth (this year) | +34.66% |
Earnings growth (next 5 years) | +1.50% |
Revenue growth (last year) | +22.88% |
P/E ratio | NM |
Price/Sales | 27.88 |
Price/Book | -- |
Today’s change | Today’s % change | |
---|---|---|
HZNPHorizon Therapeutics... | +0.09 | +0.08% |
ESAIYEisai Co Ltd | -0.13 | -0.86% |
---- | ||
INCYIncyte Corp | -0.23 | -0.38% |
Next reporting date | October 26, 2023 |
EPS forecast (this quarter) | -$1.53 |
Annual revenue (last year) | $1.0B |
Annual profit (last year) | -$1.1B |
Net profit margin | -109.04% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |